Share

June 2022; 12 (3) Five New Things

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Five New Things

Chafic Karam
First published January 27, 2022, DOI: https://doi.org/10.1212/CPJ.0000000000001150
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1084

Share

Article Information

vol. 12 no. 3 258-262
DOI: 
https://doi.org/10.1212/CPJ.0000000000001150
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received September 23, 2021
  • Accepted December 10, 2021
  • First Published January 27, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Chafic Karam, MD
  1. Chafic Karam, MD
    2. Scientific Advisory Boards:

    1. I served on DMSB for a Phase 2/3 Trial of Arimoclomol in Inclusion Body Myositis (IBM)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received speaker honoraria from Akcea, Alnylam,Biogen, Genzyme and CSL behring.

    Editorial Boards:

    1. I served on the editorial board of the Neurology Resident and Fellow section. I served as Deputy Editor, Neurology Write Click, Dispute and Debate.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have received consulting honoraria from Akcea, Alnylam, Alexion, Biogen, Cytokinetics, Genzyme and CSL Behring.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology, University of Pennsylvania, Philadelphia.
  1. Correspondence
    Dr. Karam chafic.karam{at}pennmedicine.upenn.edu
View Full Text

Article usage

Article usage: January 2022 to April 2023

AbstractFullPdfSource
Jan 2022230019Highwire
Feb 202226380415Highwire
Mar 2022375056Highwire
Apr 2022283038Highwire
May 2022203016Highwire
Jun 20222193303198Highwire
Jul 202213869372Highwire
Aug 202211316659Highwire
Sep 202212043947Highwire
Oct 20225703339Highwire
Nov 20229724045Highwire
Dec 20223302824Highwire
Jan 202334588Highwire
Feb 20232951017Highwire
Mar 20232691111Highwire
Apr 20232801420Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me